Posted by Michael Wonder on 18 Oct 2023
AbbVie's Rinvoq (upadacitinib) receives Health Canada approval as the first and only oral therapy for the treatment of adults with moderately to severely active Crohn's disease
17 October 2023 - Approval is based on results from three Phase 3 clinical trials demonstrating Rinvoq achieved the co-primary outcomes of clinical remission and endoscopic response as induction and maintenance treatment.
AbbVie today announced that Health Canada has approved Rinvoq (upadacitinib, 45 mg [induction dose] and 15 mg and 30 mg [maintenance dose]), an oral, once daily selective and reversible JAK inhibitor, for the treatment of adults with moderately to severely active Crohn's disease.
